Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021, at 11:00 AM ET. This event will take place virtually, and a live webcast will be accessible on the Company’s website under the ‘Events and Presentations’ section. A replay will be available for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, with QINLOCK being its FDA-approved medication for fourth-line gastrointestinal stromal tumors (GIST).

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021 at 11:00 AM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005246/en/

FAQ

When will Deciphera Pharmaceuticals' CEO participate in the Guggenheim Healthcare Talks?

Steve Hoerter, CEO of Deciphera Pharmaceuticals, will participate in a fireside chat on February 11, 2021, at 11:00 AM ET.

What is the focus of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals is focused on discovering and developing new medicines aimed at improving the lives of people with cancer.

Where can I watch the webcast of the Guggenheim Healthcare Talks event?

The webcast will be available on Deciphera's website under the ‘Events and Presentations’ section.

What is QINLOCK and its approval status?

QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for fourth-line gastrointestinal stromal tumors (GIST), also approved in Canada and Australia.

How long will the webcast replay of the event be available?

The replay of the webcast will be archived for 90 days following the presentation.